From:  Bile-based liquid biopsy in cholangiocarcinoma: current evidence, clinical applications and future directions

 Comparison of tissue, plasma ctDNA and bile cfDNA as specimen sources in CCA.

Comparison criterionTissuePlasma ctDNABile cfDNA
Primary roleHistological diagnosis, grading, immunohistochemistry, baseline NGSLongitudinal monitoring, MRD detection, recurrence surveillanceLocal molecular characterisation, diagnosis of indeterminate biliary strictures
InvasivenessInvasive (biopsy, brushing, surgery)Minimally invasive (venepuncture)Procedurally invasive (ERCP, PTBD, surgery)
RepeatabilityLimited; tissue exhaustion is a real concernHigh; suitable for serial samplingLow; requires biliary access at each time point
Tumour fractionHigh when cellularity is adequate; low in desmoplastic/necrotic samplesVariable; low in early/localised diseaseHigher than plasma in biliary malignancies; enriched in long DNA fragments
Spatial heterogeneityLimited; single biopsy may miss intratumoural heterogeneityMay capture systemic heterogeneity in advanced diseaseMay capture heterogeneity along biliary tree; affected by sampling site vs tumour location
Fusion detectionGood with RNA-based or hybrid-capture NGSModerate; dependent on assay design and ctDNA fractionPotentially limited; RNA stability and extraction reproducibility in bile are less established, and fusion detection depends on assay design and input quality
Current evidenceStandard of care; required for histological diagnosis and molecular profiling [1–3]Strongest evidence for postoperative MRD and recurrence monitoring [37, 38]Most mature for indeterminate biliary strictures [9] and PSC surveillance [19, 20]
When preferredWhenever adequate material is available; required for histological diagnosisSerial monitoring after surgery; when tissue is unavailable and rapid results are neededWhen biliary access is already indicated and tissue is insufficient or plasma is uninformative
Key limitationsInadequate cellularity (CCA); DNA exhaustion; fails to capture tumour evolution over timeLow ctDNA fraction in early/localised disease; reduced sensitivity for fusions and CNVsRequires invasive procedure; affected by cholangitis, stents, sampling site; not suitable for serial monitoring

cfDNA: cell-free DNA; CNV: copy number variation; ctDNA: circulating tumour DNA; ERCP: endoscopic retrograde cholangiopancreatography; MRD: minimal residual disease; NGS: next-generation sequencing; PSC: primary sclerosing cholangitis; PTBD: percutaneous transhepatic biliary drainage.